IRX Therapeutics acquired by Brooklyn ImmunoTherapeutics

This article was originally published here

This name reflects the company’s focus on advancing the science of cytokine-based immunotherapy for the treatment of a range of cancers. Brooklyn ImmunoTherapeutics general partner and board chair

The post IRX Therapeutics acquired by Brooklyn ImmunoTherapeutics appeared first on Pharma Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply